Modelling the Financial Framework of the Pharmacotherapy Cost of Rare Diseases with Orphan Medicines

ISSN Print: 2152-7245
ISSN Online: 2152-7261
www.scirp.net/journal/me
E-mail: [email protected]

Citations

"Modelling the Financial Framework of the Pharmacotherapy Cost of Rare Diseases with Orphan Medicines—Part II"
written by Albena Zlatareva, Konstantin Tachkov, Milena Stoicheva, Svetla Georgieva, Maria Krasteva Bozhkova, Guenka Petrova,
published by Modern Economy, Vol.5 No.5, 2014

has been cited by the following article(s):

[1]	Clinical and economic assessment of nusinersen: the Bulgarian perspective
	2020

[2]	СЪЩНоСт И ИзПоЛзвАНЕ НА ИкоНоМИЧЕСкИ АНАЛИзИ ПРИ ПРовЕЖДАНЕ НА НАУЧНоИзСЛЕДовАтЕЛСкА РАзРАботкА
	Тзуни, 2020

[3]	Orphan medicinal products' access to the Bulgarian pharmaceutical market–challenges and obstacles
	Expert Opinion on Orphan Drugs, 2018

[1]	Access to Orphan Medicinal Products in Bulgaria: An Analysis of the Positive Drug List and Individual Access Schemes Healthcare, 2025 DOI:10.3390/healthcare13182258

[2]	Clinical and economic assessment of nusinersen: the Bulgarian perspective Expert Opinion on Orphan Drugs, 2020 DOI:10.1080/21678707.2020.1835641

[3]	Orphan medicinal products’ access to the Bulgarian pharmaceutical market – challenges and obstacles Expert Opinion on Orphan Drugs, 2017 DOI:10.1080/21678707.2018.1421063

Top